PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1677450-3 1991 In the present in vitro study, the formation in human T cells (MOLT-4, ATH8, and CCRF-CEM) of the pharmacologically active metabolite of ddIno and ddAdo, 2",3"-dideoxyadenosine-5"-triphosphate (ddATP), was found to be stimulated 2-4-fold by appropriate concentrations of inosinate dehydrogenase (IMPD) inhibitors such as ribavirin, tiazofurin, and mycophenolic acid. Didanosine 137-142 inosine monophosphate dehydrogenase 1 Homo sapiens 296-300 1677450-5 1991 No change was noted in the intracellular concentration of the corresponding physiological deoxynucleoside-5"-triphosphate, dATP; positive correlation was observed, however, between the increase in ddATP formation from ddIno and the increase in intracellular IMP occurring as a consequence of IMPD inhibition. Didanosine 218-223 inosine monophosphate dehydrogenase 1 Homo sapiens 292-296 1677450-6 1991 The results support the hypothesis that the stimulation of ddATP formation seen when ddIno is combined with ribavirin or other IMPD inhibitors is a consequence of an increased concentration of IMP, the major phosphate donor for the initial phosphorylation step in the anabolism of ddIno to ddATP, i.e., ddIno----ddIMP. Didanosine 281-286 inosine monophosphate dehydrogenase 1 Homo sapiens 127-131